ReviewPolymers2026
Enzyme-Responsive Polymeric Drug Delivery Systems for the Treatment of Inflammatory Bowel Diseases: A Review.
Review in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polymer Nanoparticles in Medical Applications-Future Directions.Nanomaterials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract that imposes an increasing global health burden. Conventional pharmacological treatments are often limited by systemic side effects and insufficient drug accumulation at inflamed intestinal sites. Enzyme-responsive polymeric drug delivery systems have emerged as a promising strategy to overcome these limitations by enabling site-specific and controlled drug release within the pathological microenvironment of the colon. This review summarizes recent advances in enzyme-responsive polymeric platforms designed for IBD therapy. We first discuss the altered enzymatic landscape in the intestinal microenvironment of IBD, including host-derived inflammatory enzymes such as esterases, matrix metalloproteinases, and hyaluronidase, as well as microbiota-derived enzymes such as azoreductase, cellulase, and amylase. These enzymes provide intrinsic biological triggers for selective polymer degradation and drug release. We then categorize enzyme-responsive polymeric delivery systems according to the enzymes involved and highlight representative material design strategies, including polymer prodrugs, core-shell nanocarriers, enzyme-degradable hydrogels, and polysaccharide-based carriers. Particular emphasis is placed on the multifunctional roles of polymers that enable targeted delivery, mucosal adhesion, and therapeutic synergy through bioactive degradation products. Finally, current challenges and future directions toward multi-stimuli-responsive systems and clinically translatable polymeric nanomedicine for precision IBD therapy are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.